A novel drug of elotuzumab for treatment of refractory/relapsed multiple myeloma: a meta-analysis of eight trials

doi:10.5246/jcps.2017.07.059

Journal of Chinese Pharmaceutical Sciences ›› 2017, Vol. 26 ›› Issue (7): 528-533.DOI: 10.5246/jcps.2017.07.059

• Drug administration and clinical pharmacy column • Previous Articles Next Articles

A novel drug of elotuzumab for treatment of refractory/relapsed multiple myeloma: a meta-analysis of eight trials

Lin Zhang^1*, Jiewei Ding¹, Yang Wang², Xiaoxuan Jin³, Weidong Ge⁴, Shuting Huang³, Yuting Li³

1. Department of Pharmacy, Shaoxing People’s Hospital, Shaoxing Hospital of Zhejiang University, Shaoxing 312000, Zhejiang
2. Frontage Laboratories, Inc, 700 Pennsylvania Dr, Exton, PA 19341, USA
3. School of Pharmacy, College of Chemistry and Chemical Engineering, Shaoxing University, Shaoxing 312000, Zhejiang
4. Department of Ultrasonography, Zhejiang Provincial People’s Hospital, Hangzhou 310014, Zhejiang

Received:2017-03-25 Revised:2017-04-15 Online:2017-07-28 Published:2017-04-30
Contact: Tel.: +86-18258035799, +86-0575-88228650, E-mail: zl9099@126.com
Supported by:
Zhejiang Public Welfare Technology Application Research Project (Grant No. 2015C33285), Zhejiang Provincial Natural Science Foundation Project (Grant No. LY14H300002), Shaoxing Science and Technology Bureau General Project (Grant No. 2015B70070) and Zhejiang Medical and Health General Research Program (Grant No. 2013KYB030).

Abstract

Abstract:

Elotuzumab was approved by the US FDA in 2015 as a new drug for the treatment of multiple myeloma (MM), and it became a new choice for MM patients. The drug is the first immunostimulatory drug to treat MM and used to treat recurrent/refractory multiple myeloma (R/RMM) in combination with lenalidomide and dexamethasone. Therefore, we collected the reports from existing clinical trials to analyze the efficacy of the drug in clinical applications to better evaluate the effects of the drug on R/RMM. The search strategy used “elotuzumab” and “multiple myeloma” as keywords to search from the database of Cochrane, Embase, PubMed and Medline. The heterogeneity among the studies was assessed using the Cochrane χ² test, and its extent was evaluated using I² statistics. A P value of less than 0.05 was considered as statistically significant. All meta-analyses were conducted with R Software 3.3.2. We identified eight prospective studies consisting of 608 MM patients. The meta-analysis showed that the overall response rate (ORR) was 63%, 162 patients (26.6%) achieved a very good partial response rate (VGPR), and 34 patients (5.59%) achieved complete response rate (CR). The most common adverse effects of the drug included anemia, lymphopenia, thrombocytopenia, neutropenia and fatigue. Therefore, elotuzumab combination regimens offered clinical benefits to R/RMM patients, and such a combination therapy was a suitable option for continuous treatment for R/RMM patients.

Key words: Elotuzumab, Meta-analysis, Refractory/Relapsed multiple myeloma

CLC Number:

R969.4

Supporting:

Lin Zhang, Jiewei Ding, Yang Wang, Xiaoxuan Jin, Weidong Ge, Shuting Huang, Yuting Li. A novel drug of elotuzumab for treatment of refractory/relapsed multiple myeloma: a meta-analysis of eight trials[J]. Journal of Chinese Pharmaceutical Sciences, 2017, 26(7): 528-533.

References

[1] Terpos, E.; International Myeloma, S. Clin. Lymphoma Myeloma Leuk. 2017.

[2] Chan, H.S.H.; Chen, C.I.; Reece, D.E. Curr. Hematol. Malig. Rep. 2017, 12, 96-108.

[3] Zhang, L.; Jin, X.; Huang, S.; Xu, W.; Ding, J. J. Chin. Pharm. Sci. 2017, 26, 222-229.

[4] Jakubowiak, A.; Offidani, M.; Pégourie, B.; De La Rubia, J.; Garderet, L.; Laribi, K.; Bosi, A.; Marasca, R.; Laubach, J.; Mohrbacher, A.; Carella, A.M.; Singhal, A.K.; Tsao, L.C.; Lynch, M.; Bleickardt, E.; Jou, Y.M.; Robbins, M.; Palumbo, A. Blood. 2016, 127, 2833-2840.

[5] Jakubowiak, A.J.; Benson, D.M.; Bensinger, W.; Siegel, D.S.; Zimmerman, T.M.; Mohrbacher, A.; Richardson, P.G.; Afar, D.E.; Singhal, A.K.; Anderson, K.C. J. Clin. Oncol. 2012, 30, 1960-1965.

[6] Lonial, S.; Dimopoulos, M.; Palumbo, A.; White, D.; Grosicki, S.; Spicka, I.; Walter-Croneck, A.; Moreau, P.; Mateos, M.V.; Magen, H.; Belch, A.; Reece, D.; Beksac, M.; Spencer, A.; Oakervee, H.; Orlowski, R. Z.; Taniwaki, M.; Röllig, C.; Einsele, H.; Wu, K.L.; Singhal, A.; San-Miguel, J.; Matsumoto, M.; Katz, J.; Bleickardt, E.; Poulart, V.; Anderson, K.C.; Richardson, P. New England J. Med. 2015, 373, 621-631.

[7] Lonial, S.; Vij, R.; Harousseau, J. L.; Facon, T.; Moreau, P.; Mazumder, A.; Kaufman, J.L.; Leleu, X.; Tsao, L.C.; Westland, C.; Singhal, A.K.; Jagannath, S. J. Clin. Oncol. 2012, 30, 1953-1959.

[8] Mateos, M.V.; Granell, M.; Oriol, A.; Martinez-Lopez, J.; Blade, J.; Hernandez, M.T.; Martín, J.; Gironella, M.; Lynch, M.; Bleickardt, E.; Paliwal, P.; Singhal, A.; San-Miguel, J. British J. Haematology. 2016, 175, 448-456.

[9] Richardson, P.G.; Jagannath, S.; Moreau, P.; Jakubowiak, A.J.; Raab, M.S.; Facon, T.; Vij, R.; White, D.; Reece, D.E.; Benboubker, L.; Zonder, J.; Tsao, L.C.; Anderson, K.C.; Bleickardt, E.; Singhal, A.K.; Lonial, S.; Investigators, S. Lancet. Haematology. 2015, 2, 516-527.

[10] Zonder, J.A.; Mohrbacher, A.F.; Singhal, S.; van Rhee, F.; Bensinger, W.I.; Ding, H.; Fry, J.; Afar, D.E.; Singhal, A.K. Blood. 2012, 120, 552-559.

[11] Iida, S.; Nagai, H.; Kinoshita, G.; Miyoshi, M.; Robbins, M.; Pandya, D.; Bleickardt, E.; Chou, T. Int. J. Hematol. 2017, 105, 326-334.

[12] Podar, K.; Jager, D. Curr. Cancer Drug Targets. 2017, 17, 1-24.

[13] Jung, S.H.; Lee, H.J.; Vo, M.C.; Kim, H.J.; Lee, J.J. Crit. Rev. Oncol. Hematol. 2017, 111, 87-93.

[14] Chung, C. Pharmacotherapy. 2017, 37, 129-143.

[15] Neri, P.; Bahlis, N.J.; Lonial, S. Clin. Cancer Res. 2016, 22, 5959-5965.

[16] Laubach, J.P.; Paba Prada, C.E.; Richardson, P.G.; Longo, D.L. Clin. Pharmacol. Ther. 2017, 101, 81-88.

[17] Friend, R.; Bhutani, M.; Voorhees, P.M.; Usmani, S.Z. Drug Design, Develop. and Therapy. 2017, 11, 893-900.

[18] Magen, H.; Muchtar, E. Therapeutic Advances Hematology. 2016, 7, 187-95.

[19] Balasa, B.; Yun, R.; Belmar, N.A.; Fox, M.; Chao, D.T.; Robbins, M.D.; Starling, G.C.; Rice, A.G. Cancer Immunol. Immunother: CII. 2015, 64, 61-73.

[20] Mantaj, J.; Jackson, P.J.; Rahman, K.M.; Thurston, D.E. Angew Chem. Int. Ed. Engl. 2017, 56, 462-488.

[21] Yao, H.; Jiang, F.; Lu, A.; Zhang, G. Int. J. Mol. Sci. 2016, 17, 194.

[22] Wilkins, O.; Keeler, A. M.; Flotte, T.R. Hum Gene Ther. Methods. 2017, 28, 61-66.

[23] Jaspers, J.E.; Brentjens, R.J. Pharmacol. Ther. doi:10.1016/j.pharmthera.2017.03.012.

A novel drug of elotuzumab for treatment of refractory/relapsed multiple myeloma: a meta-analysis of eight trials

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Gedi Zhang, Gengxin Liu, Ziyou Yan. Therapeutic efficacy evaluation and mechanism of action based on meta-analysis and network pharmacology of Li Chong Decoction (Bolus) for cancer treatment [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(9): 720-735.
[2]	Yajing Li, Yawen Bai, Yu Du, Changhong Yan, Chunjie Ma, Lining Sun, Fengyue Bu, Haoyang Yan. Yu Ping Feng Powder for chronic glomerulonephritis treatment: A meta-analysis and network pharmacology study [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(12): 1006-1026.
[3]	Limei Su, Xiyue Mao, Limei Yang. Efficacy and safety of venous thromboembolism prevention in lung cancer: a meta-analysis of randomized controlled studies [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(10): 852-860.
[4]	Min Li, Lulu Chang, Xiangfeng Yue, Shuzhang Du. Efficacy and safety of ACEI plus tanshinone for acute exacerbation of pulmonary heart disease: a meta-analysis [J]. Journal of Chinese Pharmaceutical Sciences, 2022, 31(11): 853-865.
[5]	Yingguang Sun, Yuanyuan Yue, Jiemin Shao, Meng Gao, Yanru Deng, Yunjia Feng. A comparison of the effects of Kangfuxin liquid and watermelon frost spray for recurrent aphthous stomatitis: A meta-analysis [J]. Journal of Chinese Pharmaceutical Sciences, 2022, 31(10): 761-772.
[6]	Sibei Qin, Tong Jia, Yu Fu, Junlei Li, Xinyi Zhang, Chunsu Zhu, Guangkai Liang, Xiaoyan Nie, Luwen Shi, Yimin Cui. Association between CYP3A4 gene polymorphisms and clopidogrel response in patients with cardio-cerebrovascular diseases: a systematic review and Meta-analysis [J]. Journal of Chinese Pharmaceutical Sciences, 2021, 30(9): 762-772.
[7]	Chunxing Li, Yuanmin Zhu, Hua Liu, Zhao Xu. Efficacy of prokinetic drugs in combination with proton pump inhibitors versus proton pump inhibitors alone in the treatment of gastroesophageal reflux disease: a meta-analysis [J]. Journal of Chinese Pharmaceutical Sciences, 2021, 30(4): 347-356.
[8]	Ruirui Zhou, Liqun Wang, Tong Sun, Ziyang Wu, Xiaohui Xie. The efficacy and safety of three types of combination therapies in patients with moderate to very severe COPD: a systematic review and meta-analysis [J]. Journal of Chinese Pharmaceutical Sciences, 2019, 28(7): 502-518.
[9]	Zhiyong Dong, Xiantu Qiu, Stacy A. Kujawa, S.M. Shariful Islam, Jie Zhang. Cinobufacini injection for moderate and advanced primary liver cancer: A systematic review and meta-analysis [J]. Journal of Chinese Pharmaceutical Sciences, 2019, 28(4): 264-275.
[10]	Yao Song, Xiaofei Zhi, Hongyu Zhao, Xingqin Zhou, Wenjuan Chen, Naofumi Mukaida, Qing Lin, Bin Ji. Meta-analysis of the effect of statin use and pancreatic cancer risk [J]. Journal of Chinese Pharmaceutical Sciences, 2019, 28(12): 855-867.
[11]	Yi Zhou, Jun Wang, Long Zhang. Statin therapy on pulmonary function in patients with COPD: a meta-analysis of randomized controlled trials [J]. Journal of Chinese Pharmaceutical Sciences, 2018, 27(4): 281-288.
[12]	Ruirui Xiao, Xiuqin Xu, Lei Sun, Xiaolei Fang, Peng Xiao. Safety of ivabradine, a heart rate lowering drug: a systematic review and meta-analysis [J]. Journal of Chinese Pharmaceutical Sciences, 2017, 26(5): 379-389.
[13]	Lin Zhang, Xiaoxuan Jin, Shuting Huang, Wenyu Xu, Jiewei Ding. Analysis of the efficacy and safety of carfilzomib and its combination in multiple myeloma [J]. Journal of Chinese Pharmaceutical Sciences, 2017, 26(3): 222-229.
[14]	Dehua Zhao, Mingming Chu, Jing Chen, Jisheng Wang. Meta-analysis of gemcitabine at 30 min standard-dose infusion versus prolonged low-dose infusion for advanced non-small cell lung cancer [J]. Journal of Chinese Pharmaceutical Sciences, 2017, 26(10): 763-770.
[15]	Ru Han, Yajing An, Rongsheng Zhao. Additive effect of α-ketoacids in chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials [J]. Journal of Chinese Pharmaceutical Sciences, 2017, 26(1): 63-75.